UBS Group
IMCR icon

UBS Group’s Immunocore IMCR Stock Holding History

UBS Group’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$416K Sell
13,101
-29,033
-69% -$859K ﹤0.01% 6358
2026
Q1 		$1.27M Buy
42,134
+34,916
+484% +$1.13M ﹤0.01% 5350
2025
Q4 		$251K Sell
7,218
-34,016
-82% -$1.2M ﹤0.01% 6462
2025
Q3 		$1.5M Buy
41,234
+18,682
+83% +$635K ﹤0.01% 5235
2025
Q2 		$708K Sell
22,552
-153,580
-87% -$4.77M ﹤0.01% 5732
2025
Q1 		$5.23M Buy
176,132
+35,426
+25% +$1.06M ﹤0.01% 3737
2024
Q4 		$4.15M Buy
140,706
+96,987
+222% +$3.07M ﹤0.01% 4028
2024
Q3 		$1.36M Buy
43,719
+30,520
+231% +$1.11M ﹤0.01% 4357
2024
Q2 		$447K Sell
13,199
-81
-0.6% -$4.13K ﹤0.01% 5080
2024
Q1 		$863K Buy
13,280
+11,971
+915% +$822K ﹤0.01% 4719
2023
Q4 		$89.4K Sell
1,309
-169
-11% -$8.78K ﹤0.01% 6233
2023
Q3 		$76.7K Sell
1,478
-398
-21% -$23.6K ﹤0.01% 6015
2023
Q2 		$112K Buy
1,876
+221
+13% +$12.6K ﹤0.01% 5910
2023
Q1 		$81.8K Sell
1,655
-4,894
-75% -$275K ﹤0.01% 6079
2022
Q4 		$374K Buy
6,549
+627
+11% +$35.3K ﹤0.01% 4947
2022
Q3 		$278K Sell
5,922
-1,174
-17% -$55.9K ﹤0.01% 4830
2022
Q2 		$265K Sell
7,096
-1,312
-16% -$42.6K ﹤0.01% 4708
2022
Q1 		$251K Sell
8,408
-1,037
-11% -$26.2K ﹤0.01% 5187
2021
Q4 		$323K Sell
9,445
-4,556
-33% -$165K ﹤0.01% 5316
2021
Q3 		$519K Buy
14,001
+1,987
+17% +$67.1K ﹤0.01% 4709
2021
Q2 		$469K Buy
12,014
+341
+3% +$13.2K ﹤0.01% 4776
2021
Q1 		$497K Buy
+11,673
New +$520K ﹤0.01% 4871

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

UBS Group's IMCR Position: Q2 2026 in Review

UBS Group reduced its Immunocore (IMCR) stake by 69% in Q2 2026, selling an estimated $859K and leaving 13,101 shares worth $416K. The position accounts for ﹤0.01% of the portfolio, ranked #6358.

UBS Group first reported a position in IMCR in Q1 2021 and has held it in 22 quarters since. The position peaked at $5.23M in Q1 2025. 135 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

  • UBS Group held 13,101 shares of Immunocore worth $416K as of Q2 2026.
  • UBS Group sold 29,033 Immunocore shares in Q2 2026, an estimated $859K.
  • Immunocore made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6358 holding.
  • UBS Group first reported a position in Immunocore in Q1 2021 and has held it in 22 quarters since.
  • UBS Group's Immunocore position peaked at $5.23M in Q1 2025.
  • 135 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.